Research Projects

In 2019, AE will:Ensure that the voices of people with dementia are duly included in all operating grant activities by involving its European Working Group of People with Dementia, organise at least three meetings of the group and collaborate closely with the 2nd Joint Action on Dementia and develop recommendations on dementia-friendly and dementia...

In 2020, AE will: Ensure that the voices of people with dementia are duly included in all operating grant activities and organise four meetings of the European Working Group of People with Dementia; Develop a guide for dementia-inclusive meetings, transport and venues building on the expectations and experiences of EWGPWD members; Collect...

Alzheimer Europe defines its mission as "changing perceptions, practice and policy in order to improve the access of people with dementia and their carers to treatment option and care services". To achieve its mission, Alzheimer Europe has defined the following six objectives in its Strategic Plan which covers the period of 2006-2010: Representing...

Alzheimer Europe (AE) defines its mission as "changing perceptions, practice and policy in order to improve the access of people with dementia and their carers to treatment options and care services".

Alzheimer’s disease (AD) is central to the rapidly growing and crushing ageing challenge that threatens to economically undermine today’s health care system. AD prevalence will grow to over 100m cases in 2050. AD is incurable, but can be prevented. Detecting pre-symptomatic signs of AD in at-risk groups and intervening early may be the only viable...

Alzheimer's disease (AD) is one of the most serious diseases mankind is now facing as its social and economical impacts are increasing fastly. AD is very complex and the amyloid-β (Aβ) peptide as well as metallic ions (mainly copper and zinc) have been linked to its aetiology. While the deleterious impact of Cu is widely acknowledged, intervention...

Alzheimer’s disease (AD) affects over 35 million people worldwide and yet there are currently no medicines which slow down the progress of the disease. The ADAPTED project aims to boost the development of new medicines by investigating an area of AD research which has previously received little attention – the APOE gene. The APOE gene is a well...

In addition to devastation for the patients and their families, Alzheimer’s disease (AD) generates enormous costs for the wider European economy and is an urgent health priority. There are currently no drug treatments that can cure AD or other common forms of dementia. This absence of therapeutic interventions comes from a lack of understanding...

Alzheimer’s disease (AD) is the most common form of dementia in the Western World, representing an economic and social cost of billions of euros a year. Given the changing demographics of society, these costs will only increase over the coming decades.Amyloid plaques, composed of amyloid beta peptide (Abeta), are a defining characteristic of AD...

Alzheimer’s disease (AD) is the most common cause of dementia in the elderly, and a major reason for disability and death. The time course of AD varies between different people affected, and being able to tell in advance how the disease is likely to progress would have a great value for patient, their caregivers and for all of society. In the...

Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer’s Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to diagnose AD, expensive, invasive with multiple side effects. Positron Emission Tomography (PET) scans the patient’s...